Citigroup analyst Ygal Arounian maintains Squarespace (NYSE:SQSP) with a Neutral and raises the price target from $21 to $30.
FDA Approves Nevro’s Spinal Cord Stimulation For Diabetic Neuropathy Associated Chronic Pain
The FDA has approved Nevro Corp’s (NYSE:NVRO) Senza system for treating chronic pain associated with painful diabetic neuropathy (PDN). The approval…